SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors discuss its potential U.S. expansion and speculate on a possible Nasdaq relisting, with community members pointing to strong fundamentals driving the stock. The company's growth in China, coupled with Starbucks' struggles, is fueling optimism, while others remain cautious due to past accounting issues and the stock's OTC status.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its vision, encapsulated by the phrase "Like Bitcoin But Way Higher". Active discussions involve the project's roadmap and potential, with community members emphasizing its cultural relevance and potential for growth, particularly regarding developments in the broader cannabis industry.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending as the stock experiences a significant sell-off, sparking debates among investors about potential causes, including a Bloomberg article referencing a competitor's GLP-1 product offering. The community is actively discussing whether the sell-off is an overreaction and if the company's fundamentals remain strong, while also eyeing potential bounce-back opportunities. Some traders speculate about algo manipulation and stop-loss triggers amidst the volatility.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending due to recent achievements and potential catalysts, including the registration of their Midnight aircraft with the FAA. Community members are actively discussing the company's prospects, particularly its relationship with Japan Airlines and potential military applications, while also debating whether the stock can outperform its competitor, Joby Aviation. Some investors believe upcoming events, like piloted VTOL flights and air shows, could trigger a significant price increase.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to a report of security flaws in a battlefield communications system, leading to a sharp intraday drop. While some investors are concerned about the implications of these vulnerabilities, others view the dip as a buying opportunity, citing the company's response that the issues have been addressed and the prototype nature of the system.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab ($RKLB) is trending as investors discuss its potential breakout from a multi-month base, with some targeting higher price levels. Community members are highlighting the stock's strong support and celebrating significant gains, while also weighing the risks and potential for profit-taking. The conversation also touches on the company's growth prospects and the potential impact of upcoming developments.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience is trending amid community discussion around a potential short squeeze and recent gains. Some traders cite the company's fundamentals, upcoming data readouts, and potential for a large upside. Others remain cautious, pointing to past trial failures and ongoing discussions about a possible offering.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to community excitement around potential short squeezes and speculation about upcoming news, possibly related to government contracts, after a large after-hours buy. The community is actively discussing NVIDIA collaborations and the potential for the stock to reach new all-time highs, while also debating its valuation. Discussions also include perspectives on quantum computing's broader implications and contrasting viewpoints between bulls and bears.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as retail investors and traders discuss its impressive recent gains and potential for future growth within the quantum computing sector. Community members are weighing the possibility of a short squeeze against concerns of overvaluation and a potential offering, while some highlight a recent purchase order announcement. The stock's momentum is drawing attention, with debates swirling around its long-term prospects compared to others in the quantum computing space.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending amid speculation of a potential buyout, with community members pointing to increased volume and options activity as possible indicators. Chatter suggests that a big tech company could be interested in acquiring the AI firm to bolster its own AI capabilities. Despite recent financial results and leadership changes, the stock is seeing increased interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?

Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are expected in late 2025.

BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy? 

BDTX and Cullinan advance next-gen EGFR inhibitors, but silevertinib's potential and valuation tilt momentum toward BDTX.

Has Black Diamond Therapeutics (BDTX) Outpaced Other Medical Stocks This Year?

Here is how Black Diamond (BDTX) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.

Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?

Black Diamond sharpens focus on silevertinib after outlicensing BDTX-4933, cutting costs, and securing cash runway into late 2027.

BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?

Black Diamond shines with a 51.1% stock surge, fueled by silevertinib's progress and pipeline momentum in oncology.

Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX?

Black Diamond focuses on silevertinib for NSCLC and GBM, with key trial readouts due in late 2025 and FDA feedback expected in 2026.

Black Diamond (BDTX) Upgraded to Strong Buy: Here's Why

Black Diamond (BDTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Are Medical Stocks Lagging  Black Diamond Therapeutics (BDTX) This Year?

Here is how Black Diamond (BDTX) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.

Shares of Black Diamond Therapeutics, Inc. (BDTX) jumped around 21% as of Wednesday noon after the company announced it had entered into a <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.blackdiamondtherapeutics.com/news-releases/news-release-details/servier-and-black-diamond-therapeutics-announce-global-licensing">licensing agreement</a> with Servier, a French pharmaceutical group.As part of the deal, Servier will develop and commercialize the clinical-stage oncology company’s BDTX-4933, a molecule designed to address solid tumors, including non-small cell lung cancer.Under the agreement, Black Diamond will receive an upfront payment of $70 million and can receive up to $710 million in future payments, including development and commercial sales milestone payments and tiered royalties based on net sales.The company said earlier this month that its cash, cash equivalents, and investment of $98.6 million as of the end of 2024 would be sufficient to fund operations and capital expenditure requirements into the last quarter of 2026.On Stocktwits, retail sentiment around Black Diamond’s stock rose to a year-high, jumping higher within the ‘extremely bullish’ territory (100/100). Meanwhile, message volume surged to ‘extremely high’ levels from ‘high’ in the past 24 hours.<figure class="image"><img style="aspect-ratio:810/187;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_03_19_140848_png_e163bd613a.webp" alt="Black Diamond Therapeutics' Sentiment Meter and Message Volume as of 2:00 p.m. ET on March 19, 2025 | Source: Stocktwits" width="810" height="187"><figcaption>Black Diamond Therapeutics' Sentiment Meter and Message Volume as of 2:00 p.m. ET on March 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for the shares rising as high as $6 from its current value of over $2.&nbsp;<stembedurl>https://stocktwits.com/DaSqueeza/message/608568813</stembedurl>Another opined that a “strong reversal” is coming for the stock.<stembedurl>https://stocktwits.com/alecsalaur198/message/608560099</stembedurl><a href="https://stocktwits.com/symbol/BDTX">Black Diamond shares</a> are down by over 50% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/morgan-stanley-in-spotlight-after-reports-of-workforce-reduction/ch7kWQlRb2g">Morgan Stanley In Spotlight After Reports Of Workforce Reduction, Retail’s Yet To React</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Image Is A Part Of A Series On Pulmonary Pathologies. (Photo By BSIP/UIG Via Getty Images)

Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High

As part of the deal, Servier will develop and commercialize the clinical-stage oncology company’s BDTX-4933, a molecule designed to address solid tumors, including non-small cell lung cancer. 

Equity

Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug

Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With a 36% objective response rate and encouraging durability, BDTX-1535 shows...

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

Black Diamond Therapeutics Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

BDTX
Black Diamond Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BDTX News

BDTX Black Diamond Therapeutics Inc